Baxter International Inc. Share Price Target ‘$43.83’, now 24.3% Upside Potential

DirectorsTalk Interviews

Baxter International Inc. which can be found using ticker (BAX) now have 12 confirmed analysts covering the stock with the consensus suggesting a rating of ‘hold’. The range between the high target price and low target price is between $54.00 and $39.00 with the average share target price sitting at $43.83. (at the time of writing). Now with the previous closing price of $35.25 this is indicating there is a potential upside of 24.3%. It’s also worth noting that there is a 50 day moving average of $40.06 and the 200 moving average now moves to $38.68. The market capitalization for the company is 17.85B. The stock price for the company is currently $35.02 USD

The potential market cap would be $22,189,160,333 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $29.39 and a 3.54% return on assets.

Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s segments include Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia-Pacific), and Hillrom. The Americas, EMEA and APAC segments provide a portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals, and surgical hemostat and sealant products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.

Share on:

Latest Company News

Ilika plc Advances Solid-State Batteries With 10Ah Goliath Breakthrough (Video)

Ilika plc has shipped its 10Ah Goliath solid-state battery prototypes, marking a major scale-up from earlier designs. CEO Graeme Purdy outlines how higher-energy materials and an automated pilot line delivered a 93% yield, signalling readiness for larger-scale manufacturing.

Harbour Energy to acquire Waldorf subsidiaries in $170m deal, boosting UK production

Harbour Energy has agreed to acquire most subsidiaries of Waldorf Energy Partners and Waldorf Production for $170 million, a move expected to add 20 kboepd of oil weighted production and 35 mmboe of 2P reserves.

TwentyFour Income Fund reports positive month as ABS and CLO issuance hits post-crisis highs

TwentyFour Income Fund noted improved market sentiment in November, supported by progress in Ukraine peace discussions and a stable UK Budget response.

GSK RSV vaccine recommended for wider adult use, CHMP backs expansion

GSK has announced that the EMA’s CHMP has recommended broadening the indication of its adjuvanted RSV vaccine to adults aged 18 and over, with a final decision expected in February 2026.

UK equities regain investor interest as valuation opportunities widen

Fidelity Special Values manager Alex Wright says UK equities have seen renewed interest as valuations remain attractive compared with global peers. The trust continues to follow a contrarian approach, focusing on undervalued mid and small cap companies and aiming to identify positive change not yet reflected in share prices.

Global Opportunities Trust reaffirms successful value and absolute-return strategy (LON: GOT)

As at the end of October 2025, Global Opportunities Trust continued to apply its value focused strategy across global markets, holding a blend of equities, private market investments and significant liquidity positions.

    Search

    Search